The Top 5 Biosimilar Articles for the Week of June 7

Here are the top 5 biosimilar articles for the week of June 7, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of June 7, 2021.

Number 5: Bio-Thera Solutions initiated a phase 3 clinical study for its golimumab biosimilar candidate (BAT2506) referencing Simponi.

Number 4: Organon said that it will do marketing but not research and development, Biogen and Bio-Thera moved forward with a tocilizumab candidate, and Lupin promoted a pegfilgrastim biosimilar.

Number 3: Investigators further elucidated the equivalence of a trastuzumab biosimilar vs Herceptin in HER2+ (human epidermal growth factor receptor 2–positive) breast cancer.

Number 2: When biosimilars emerged in oncology, oncologists dipped in a toe and then got serious, according to a retrospective study on usage and savings presented at ASCO 2021.

Number 1: Sarfaraz K. Niazi, PhD, a member of The Center for Biosimilars® Advisory Board, reported on his citizen petition to the FDA to rationalize testing of biosimilars.

To read all of these articles and more, visit centerforbiosimilars.com.